ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Shares Acquired by Wedge Capital Management L L P NC

Wedge Capital Management L L P NC increased its holdings in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 3.1% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 65,531 shares of the specialty pharmaceutical company’s stock after purchasing an additional 1,958 shares during the period. Wedge Capital Management L L P NC’s holdings in ANI Pharmaceuticals were worth $3,613,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently added to or reduced their stakes in the stock. New York State Teachers Retirement System boosted its position in shares of ANI Pharmaceuticals by 0.9% in the third quarter. New York State Teachers Retirement System now owns 22,180 shares of the specialty pharmaceutical company’s stock worth $1,288,000 after buying an additional 200 shares during the period. China Universal Asset Management Co. Ltd. boosted its position in shares of ANI Pharmaceuticals by 93.6% in the third quarter. China Universal Asset Management Co. Ltd. now owns 513 shares of the specialty pharmaceutical company’s stock worth $30,000 after buying an additional 248 shares during the period. Oregon Public Employees Retirement Fund boosted its position in shares of ANI Pharmaceuticals by 9.2% in the third quarter. Oregon Public Employees Retirement Fund now owns 4,754 shares of the specialty pharmaceutical company’s stock worth $276,000 after buying an additional 400 shares during the period. Arizona State Retirement System boosted its position in shares of ANI Pharmaceuticals by 9.9% in the third quarter. Arizona State Retirement System now owns 4,589 shares of the specialty pharmaceutical company’s stock worth $266,000 after buying an additional 415 shares during the period. Finally, Maryland State Retirement & Pension System boosted its position in shares of ANI Pharmaceuticals by 8.8% in the third quarter. Maryland State Retirement & Pension System now owns 5,901 shares of the specialty pharmaceutical company’s stock worth $343,000 after buying an additional 476 shares during the period. 76.05% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on ANIP shares. Truist Financial upped their target price on ANI Pharmaceuticals from $72.00 to $80.00 and gave the stock a “buy” rating in a research report on Friday, March 1st. Guggenheim reaffirmed a “buy” rating and issued a $77.00 target price on shares of ANI Pharmaceuticals in a research report on Tuesday. HC Wainwright upped their target price on ANI Pharmaceuticals from $73.00 to $83.00 and gave the stock a “buy” rating in a research report on Monday, March 4th. Finally, Capital One Financial assumed coverage on ANI Pharmaceuticals in a research report on Friday, March 15th. They issued an “overweight” rating and a $80.00 target price for the company. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, ANI Pharmaceuticals presently has an average rating of “Buy” and a consensus target price of $80.00.

ANI Pharmaceuticals Stock Down 1.1 %

Shares of ANI Pharmaceuticals stock opened at $65.43 on Thursday. The company has a current ratio of 3.57, a quick ratio of 2.81 and a debt-to-equity ratio of 0.66. The business’s 50 day simple moving average is $65.34 and its 200-day simple moving average is $58.75. The stock has a market capitalization of $1.38 billion, a price-to-earnings ratio of 77.89 and a beta of 0.79. ANI Pharmaceuticals, Inc. has a twelve month low of $36.99 and a twelve month high of $70.81.

ANI Pharmaceuticals (NASDAQ:ANIP) last posted its earnings results on Thursday, February 29th. The specialty pharmaceutical company reported $0.78 EPS for the quarter, beating the consensus estimate of $0.58 by $0.20. ANI Pharmaceuticals had a return on equity of 18.06% and a net margin of 3.86%. The firm had revenue of $131.65 million for the quarter, compared to analysts’ expectations of $123.02 million. Equities research analysts forecast that ANI Pharmaceuticals, Inc. will post 3.55 earnings per share for the current year.

Insider Activity at ANI Pharmaceuticals

In related news, COO Muthusamy Shanmugam sold 16,809 shares of the firm’s stock in a transaction that occurred on Friday, April 19th. The stock was sold at an average price of $65.17, for a total value of $1,095,442.53. Following the sale, the chief operating officer now directly owns 782,620 shares in the company, valued at approximately $51,003,345.40. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other news, CEO Nikhil Lalwani sold 28,965 shares of the firm’s stock in a transaction on Wednesday, March 6th. The stock was sold at an average price of $65.52, for a total transaction of $1,897,786.80. Following the completion of the sale, the chief executive officer now directly owns 444,981 shares of the company’s stock, valued at approximately $29,155,155.12. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, COO Muthusamy Shanmugam sold 16,809 shares of the firm’s stock in a transaction on Friday, April 19th. The stock was sold at an average price of $65.17, for a total value of $1,095,442.53. Following the sale, the chief operating officer now directly owns 782,620 shares of the company’s stock, valued at $51,003,345.40. The disclosure for this sale can be found here. Insiders have sold a total of 156,803 shares of company stock worth $10,363,466 in the last three months. 12.70% of the stock is owned by company insiders.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.